Evolving Treatment Approaches in EGFR- Mutated NSCLC: First-Line Therapies and AE Management
Dr. Husain, MD, discusses how new clinical data from ELCC 2025, including findings from MARIPOSA and FLAURA-2, are redefining first-line treatment and sequencing strategies for EGFR-mutant NSCLC to improve long-term outcomes and CNS control.

Featured Video

Updated Data from MARIPOSA: ELCC 2025 Dr. Husain discusses how updated MARIPOSA and FLAURA-2 data highlight the growing role of combination regimens in improving both systemic and CNS outcomes for patients with EGFR-mutant NSCLC.   WATCH NOW